Literature DB >> 9848759

The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study.

M Riaz1, R Porat, N L Brodsky, H Hurt.   

Abstract

OBJECTIVE: To evaluate the effects of maternal magnesium sulfate treatment on newborn outcome.
METHODS: Subjects were newborn infants delivered at > or = 34 weeks of gestation whose mothers received a minimum of 12 hours of intravenous MgSO4 therapy before delivery. Control infants were the next born infants of similar gestational age. Outcome recorded at delivery included Apgar scores, whether resuscitation was required, and whether respiratory depression or decreased tone were noted by the physician in attendance. Pneumocardiograms on magnesium-exposed and control infants, obtained within 6 to 18 hours after delivery, were analyzed postdischarge by a single investigator who was blinded to group. The nursery course, feeding patterns, time to first stool, and time to first void were recorded. All patient care decisions, including admission to the neonatal intensive care unit (NICU) or term nursery, were independent of study protocol.
RESULTS: A total of 26 magnesium-exposed and 26 control infants were enrolled. The mean total dose of MgSO4 before delivery was 51.2+/-24 gm; the mean duration of therapy was 23.1+/-10 hours. The mean maternal serum magnesium level before delivery was 5.8+/-1.1 mg/dl. The infants' mean cord or initial serum magnesium level was 5.2+/-1.0 mg/dl, which correlated with the maternal magnesium level before delivery (r=0.81, p < 0.001). MgSO4-exposed infants had a higher incidence of hypotonia and lower median Apgar scores than control infants (p < 0.001). However, there was no association between adverse outcomes and maternal serum magnesium concentrations at delivery, duration of treatment, or dose of MgSO4. No difference in dose or length of maternal MgSO4 treatment was noted between infants admitted to term nursery and those admitted to NICU. Pneumocardiogram data were similar between MgSO4-exposed and control infants (all p > or = 0.16). There were no significant differences in number of episodes of feeding intolerance or in time to first stool or void between MgSO4-exposed and control infants (all p > or = 0.31).
CONCLUSION: Infants born to mothers treated with MgSO4 were more likely to be hypotonic and have lower Apgar scores at birth. Beyond the immediate postdelivery period, there were no additional complications in this cohort attributable to prenatal MgSO4 exposure. We suggest that pediatricians attend deliveries of magnesium-exposed infants.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9848759

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  9 in total

1.  Pharmacological Therapy of Tachyarrhythmias During Pregnancy.

Authors:  Ameeta Yaksh; Lisette Jme van der Does; Eva Ah Lanters; Natasja Ms de Groot
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

2.  Association of cord blood magnesium concentration and neonatal resuscitation.

Authors:  Lynn H Johnson; Delicia C Mapp; Dwight J Rouse; Catherine Y Spong; Brian M Mercer; Kenneth J Leveno; Michael W Varner; Jay D Iams; Yoram Sorokin; Susan M Ramin; Menachem Miodovnik; Mary J O'Sullivan; Alan M Peaceman; Steve N Caritis
Journal:  J Pediatr       Date:  2011-11-04       Impact factor: 4.406

3.  Effect of perinatal factors on time of first stool passage in preterm newborns: An open, prospective study.

Authors:  Hande Gulcan; Serdal Gungor; Filiz Tiker; Hasan Kilicdag
Journal:  Curr Ther Res Clin Exp       Date:  2006-05

4.  Magnesium sulfate exposure and neonatal intensive care unit admission at term.

Authors:  A I Girsen; M B Greenberg; Y Y El-Sayed; H Lee; B Carvalho; D J Lyell
Journal:  J Perinatol       Date:  2014-10-16       Impact factor: 2.521

5.  Neonatal magnesium levels are safe after maternal MgSO4 administration: a comparison between unexposed preterm neonates and neonates exposed for fetal neuroprotection or maternal eclampsia prevention-a cohort study.

Authors:  Dehaene Isabelle; Van Steenstraeten Tessa; De Coen Kris; De Buyser Stefanie; Decruyenaere Johan; Smets Koenraad; Roelens Kristien
Journal:  Eur J Pediatr       Date:  2022-05-21       Impact factor: 3.860

6.  Preeclampsia: effect on newborn blood pressure in the 3 days following preterm birth: a cohort study.

Authors:  M Reveret; A Boivin; V Guigonnis; F Audibert; A M Nuyt
Journal:  J Hum Hypertens       Date:  2014-07-03       Impact factor: 3.012

7.  Maternal magnesium sulphate exposure predicts neonatal magnesium blood concentrations.

Authors:  Catherine M T Sherwin; Alfred Balch; Sarah C Campbell; Jeunesse Fredrickson; Erin A S Clark; Michael Varner; Chris Stockmann; E Kent Korgenski; Joshua L Bonkowsky; Michael G Spigarelli
Journal:  Basic Clin Pharmacol Toxicol       Date:  2013-12-11       Impact factor: 4.080

8.  Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis.

Authors:  Emily Shepherd; Rehana A Salam; Deepak Manhas; Anne Synnes; Philippa Middleton; Maria Makrides; Caroline A Crowther
Journal:  PLoS Med       Date:  2019-12-06       Impact factor: 11.069

9.  Assessment of serum magnesium levels and its outcome in neonates of eclamptic mothers treated with low-dose magnesium sulfate regimen.

Authors:  Monalisa Das; Patralekha Ray Chaudhuri; Badal C Mondal; Sukumar Mitra; Debasmita Bandyopadhyay; Sushobhan Pramanik
Journal:  Indian J Pharmacol       Date:  2015 Sep-Oct       Impact factor: 1.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.